Rapid over-activation of b-adrenergic receptor (b-AR) upon stress leads to cardiac inflammation, a prevailing factor that underlies heart injury. However, mechanisms by which acute b-AR stimulation induce cardiac inflammation still remain unknown. Here, we set out to identify the crucial role of inflammasome/interleukin (IL)-18 in initiating and maintaining cardiac inflammatory cascades upon b-AR insult. 
Introduction
Increases in sympathetic activity are necessary during the flight-orfight response under acute stress conditions. 1 On the other hand, acute sympathetic insult induced by rapidly developing stress conditions is associated with increased risks of morbidity and mortality in cardiovascular diseases such as ischaemic disease and arrhythmias. 2 Takotsuo cardiomyopathy, also called stress cardiomyopathy, is probably the most striking example of how acute stress directly promotes heart injuries. 3 Catecholamine overload has been proposed as an important contributing factor for stress cardiomyopathy. 3 Acute stress elicits exacerbated secretion of catecholamines (epinephrine and norepinephrine), which in turn increases inflammatory and oxidative responses. 4 These cardiotoxic effects are known to arise from over-activation of b-adrenergic receptor (b-AR). Indeed, chronic b-adrenergic stimulation using isoproterenol (ISO), a non-selective b-AR agonist, is sufficient to induce expression of several myocardial proinflammatory cytokines, including tumour necrosis factor (TNF)-a, interleukin (IL)-1b, IL-6, and IL-18. 5, 6 These proinflammatory cytokines are known to contribute to myocardial damage and long-term pathological remodelling such as myocardial fibrosis. Blocking the over-activation of inflammatory responses is proposed as a promising strategy to attenuate cardiac pathological remodelling. 7 However, the precise mechanisms by which b-adrenergic insults elicit inflammatory responses in the heart are not understood. The temporal and spatial profiles of inflammatory cytokine proteins in the heart induced by b-adrenergic stimulation have not been characterized. Moreover, the type of cells and molecular mechanisms responsible for inflammatory cytokine production upon b-AR stimulation still remain unknown. These are prevailing issues in understanding the pathogenesis of numerous heart diseases that involve comorbidity of b-AR over-activation and crucial for identification of novel targets to inhibit inflammatory injury of the heart. Notably, intermittent b-adrenergic stimulation causes more severe systolic as well as diastolic ventricular dysfunction and myocardial fibrosis than sustained badrenergic stimulation. 8 In this regard, experimental models of acute b-AR stimulation may offer a feasible means to delineate how the inflammatory cascade is initiated and maintained, which in turn leads to long-term pathological remodelling in the heart and cardiac dysfunction.
In the present study, using a cytokine antibody array, we performed inflammatory cytokine profiling in the heart at various time points after ISO-induced acute b-adrenergic overactivation. We found that the initial wave of up-regulated cytokines within myocardium was primarily composed of chemokines, which promoted early macrophage infiltration specifically into the heart. Moreover, we identified that IL-18 was the crucial up-stream regulator responsible for enhancing cardiac chemokine production, which served as a critical trigger for the cardiac inflammatory cascades upon b-AR insult.
Methods
Detailed experimental procedures are described in the Supplementary material online. All mRNA and protein measurements were performed using the whole heart lysates unless otherwise noted in specific figure legends.
Results
ISO induces rapid production of inflammatory cytokines in the myocardium, leading to macrophage infiltration specifically in the heart
We first assessed the temporal and spatial patterns of inflammatory cell infiltration in the heart using immunohistochemistry at various time points after a single dose of ISO treatment. Macrophages were identified by the Mac-3 þ marker, which was the primary type of infiltrated cells in the heart in this acute b-adrenergic stimulation paradigm ( Figure 1A ). In contrast, T cells, B cells and neutrophils were not detected (see Supplementary material online, Figure S1 ). Infiltration of macrophages in the heart was clearly detected 24 h after ISO injection, which reached a peak at 72 h and then gradually disappeared 7 days after ISO treatment ( Figure 1A) . No increased macrophage infiltrations were detected in other organs examined, including liver, lung, kidney, and spleen, despite systemic administration of ISO (see Supplementary material online, Figure S1 ). Thus, heart is the most susceptible organ upon systemic b-adrenergic insult. Notably, the infiltrating macrophages upon ISO treatment are primarily dominated by proinflammatory M1 macrophages ( Figure 1B ; Supplementary material online, Figure S2 ). Increased production of cytokines is a critical mediator for inflammatory damages. Hence, we next explored the dynamic changes of cytokines in the heart upon ISO treatment using a mouse cytokine antibody array which detects 96 cytokines (see Supplementary material online, Table S1 ). As shown in Figure 1C , up-regulation of distinct functional groups of cytokines was detected at various time points. Importantly, preceding the infiltration of macrophages, 13 cytokines were increased as early as 12 h after ISO-treatment, suggesting that the initial cytokine production most likely occurs within myocardium ( Figure 1C left panel) . The up-regulated cytokines at 12 and 24 h were mainly chemokines, which conceivably act to recruit macrophages into the heart. In contrast, proinflammatory cytokines were the primary species detected 72 h after ISO treatment ( Figure 1C , right panel), suggesting execution of inflammation at this time point. GO analysis also supports the functions of distinct cytokine waves (see Supplementary material online, Figure S3 ).
The dynamic changes of several chemokines and proinflammatory cytokines were further validated by ELISA ( Figure 1D) . The increased chemokines, including monocyte chemoattractant protein (MCP)-1, MCP-5, macrophage inflammatory protein-1a (MIP-1a), and C-X-C motif chemokine 10 (CXCL-10), all reached the peak expression levels 12 h after ISO treatment ( Figure 1D ). In contrast, elevated proinflammatory cytokines, such as IL-6 and TNF-a, were not detected until 24 h, but sustained through 72 h after ISO treatment. Chemokines increased prior to the early infiltration of macrophages, including CC chemokines (MCP-1, MCP-5, and MIP-1a) and the CXC chemokine CXCL-10, are well-known monocyte chemoattractants, which likely act to promote early macrophage infiltration. Pre-treatment of propranolol, a b-AR antagonist, completely prevented ISO-induced cytokine increase and macrophage infiltration, Figure S4 ).
ISO induces inflammasome-dependent activation of IL-18, but not IL-1b, in myocardium
The pioneer wave of elevated chemokine production upon b-AR overactivation offers a clue for identification of critical up-stream regulators that trigger ISO-induced inflammatory responses. We next examined IL-1b and IL-18, both are known to enhance expression of chemokines and adhesion molecules. 9 Pro-IL-1b and pro-IL-18 need to be converted to the mature and active form by inflammasomedependent cleavage. 10 As shown in Figure 2A , ELISA assay detected a significant increase of active IL-18 at 1, 24, and 72 h in the heart after ISO treatment. In contrast, active IL-1b was not increased at the above time points. Immunoblot further confirmed that mature IL-18 began to markedly increase at 1 h after ISO treatment, preceding the elevated production of chemokines ( Figure 2B ). Consistently, caspase-1 activation, a key component in inflammasome essential for cleavage and secretion of IL-18, 10 is also increased along with IL-18 cleavage upon ISO treatment ( Figure 2B ). In contrast, cleavage of IL1b was not increased (see Supplementary material online, Figure S5) . Notably, the increase of mature IL-18 in the heart can be blocked by the b-AR antagonist propranolol (see Supplementary material online, Figure S6 ). In addition, caspase-1 activation and mature IL-18 are restricted in the heart, but not detected in other organs (see Supplementary material online, Figure S7 ), indicating that b-AR activation specifically induced IL-18 maturation in the heart. Moreover, no significant changes in the mRNA levels of IL-18 and IL1b were observed in the heart after ISO treatment (see Supplementary material online, Figure S8 ). Thus, acute b-AR activation primarily triggers inflammatory cascades in the heart through cleavage of pro-IL-18. Using immunofluorescence staining, we found that active IL-18 was predominantly detected in the cardiomyocytes at 1 h after ISO treatment ( Figure 2C , upper panel). In contrast, 24 h after ISO treatment, the majority of active IL-18 was found in Mac-3 þ macrophages ( Figure 2C , lower panel). The capability for cardiomyocytes to produce active IL-18 upon b-AR activation was further validated in isolated neonatal mouse cardiomyocytes (NMCM) where cleaved caspase-1 and IL-18 were rapidly increased 5 min after exposure to ISO, and sustained for at least 2 h ( Figure 2D ). NLRP3 (NLR family, pyrin domain-containing 3), but not NLRC4, inflammasome was activated by ISO in cardiomyocytes (see Supplementary material online, Figure S9 ). NLRP3 inhibitor MCC950 inhibited ISO induced caspase 1 and IL-18 activation in NMCM (see Supplementary material online, Figure S10 ), suggesting that the NLRP3 inflammasome is responsible for IL-18 cleavage in NMCM. Conversely, neither caspase-1 nor IL-18 was activated in isolated neonatal mouse cardiac fibroblasts (NMCF) after ISO exposure (see Supplementary material online, Figure S11 ). Nonetheless, the supernatant derived from ISO-treated cardiomyocytes can increase the secretion of MCP-1 and MCP-5 by NMCFs (see Supplementary material online, Figure S12A ). This effect was completely blocked by the treatment of wild type NMCM with the caspase-1 inhibitor (FMK) or the loss of IL-18 in IL-18-/-NMCM (see Supplementary material online, Figure S12B and C). The NLRP3 inhibitor MCC950 or the loss of NLRP3 in NMCM also blocked this effect (see Supplementary material online, Figure S13 ). These in vitro results suggest that NLRP3/caspase-1 dependent IL-18 cleavage in cardiomyocytes results in secretion of IL-18-dependent cytokines, which in turn triggers inflammatory response in cardiac fibroblasts. In summary, these results suggest that IL-18 activation initially occurs in the cardiomyocytes upon b-AR insult, which precedes and acts as a trigger for the early increase of chemokine production within the heart and macrophage infiltration. We next questioned which b-AR mediates ISO induced inflammasome activation. Pre-treatment of NMCM by bisoprolol (selective b 1 blocker) but not ICI 118 551(selective b 2 blocker) significantly blocked ISO induced inflammasome activation and ROS production in NMCM (see Supplementary material online, Figure S14A and B). In addition, NAC, a ROS scavenger, blocked ISO induced inflammasome activation in NMCM and in vivo (see Supplementary material online, Figure S14C and D). Consequently, NAC blocked ISO-induced macrophage infiltration and fibrosis (Supplementary material online, Figure S14E -G). Taken together, our studies revealed that the b 1 -AR-ROS pathway mediates ISO-induced inflammasome activation in the heart. IL-18 levels are increased in patients with sympathetic overactivation and mice treated with increasing doses of ISO To investigate whether circulating IL-18 levels are increased in human patients upon sympathetic overactivation, we measured plasma levels of norepinephrine and IL-18 in patients diagnosed with non-ST-segment elevation myocardial infarction (NSTEMI) or unstable angina (UA), and patients with excluded cardiac origin of the chest pain (non-cardiac chest pain). Plasma samples were collected on admission within 24 h after the onset of chest pain. Indeed, a positive correlation was observed between the plasma levels of norepinephrine and IL-18 activity in patients with non-ST segment elevation acute coronary syndromes and non-cardiac chest pain ( Figure 3A , Supplementary material online, Figure S15 ). In addition, patients with higher IL-18 levels showed lower fraction shortenings (FS%), which reflects reduced cardiac systolic function ( Figure 3B ). The baseline characteristics of patients were shown in Supplementary material online, Tables S2 and S3. Furthermore, in mice that received increasing doses of ISO, myocardium and serum levels of IL-18 were increased ( Figure 3C and D) . Together, these results indicate that IL-18 activity is quantitatively associated with the severity of sympathetic overactivation in patient and the ISO treated mouse model. 18-/-mice and NLRP3-/-mice were subjected to ISO treatment. The loss of IL-18 and NLRP3 in the heart was confirmed by immunoblot (see Supplementary material online, Figure S16 ). As shown in Figure  4A , ISO-induced production of chemokines (MCP-1 and MCP-5) and proinflammatory cytokine IL-6 in WT mice were severely impaired in the NLRP3-/-heart. Moreover, the loss of NLRP3 completely blocked activation of IL-18 upon ISO treatment ( Figure 4B) . As a result, ISO-induced macrophage infiltration was significantly reduced in the NLRP3-/-heart as compared with that in the WT heart ( Figure  4C) . Similarly, ISO induced expression of chemokines and macrophage infiltration were significantly attenuated in the IL-18-/-hearts ( Figure 4D and E) . These data clearly demonstrate the essential roles of NLRP3 inflammasome-dependent IL-18 activation in triggering cardiac inflammation upon b-AR over-activation.
Chemokines, but not growth factors, induced by b-AR over-activation can be selectively reversed by IL-18 nAbs
To directly test whether inhibition of IL-18 by IL-18 neutralizing antibodies (IL-18) nAbs is sufficient for blocking the inflammatory responses caused by acute b-adrenergic insult, mice were subjected to intraperitoneal injection with rat IL-18 nAbs or IgG as a negative control 1 h after ISO treatment. The effectiveness of IL-18 nAbs was confirmed by the measurement of interferon gamma (IFNc), a wellknown downstream effector of IL-18 (see Supplementary material online, Figure S17 ). Cytokine antibody array analysis revealed that IL-18 nAbs significantly reversed 25 ISO-induced cytokines selectively in the heart whereas the control IgG had no effect ( Figure 5A left panel) . There were 13 cytokines that could not be reversed by IL-18 nAbs. The percentages of these reversed and unchanged cytokines were further classified based on their function ( Figure 5A right panel) . Among the reversed cytokines, 56% were CCL or CXCL chemokines, whereas nearly half of unchanged cytokines were growth factors. Quantitatively, 73.7% chemokines, 66.7% adhesion molecules and 50% proinflammatory cytokines were reversed to the basal level after treatment with IL-18 nAbs ( Figure 5B) . ELISA assay further confirmed the levels of cytokines and growth factors in response to IL-18 nAbs detected by the cytokine array ( Figure 5C ). Thus, IL-18 nAbs selectively blocked deleterious inflammatory cytokines induced by acute b-AR stimulation, including chemokines, adhesion molecules and proinflammatory cytokines, but not beneficial growth factors.
Cardiac inflammation, fibrosis, and dysfunction induced by ISO can be ameliorated by early administration of IL-18 nAbs
To identify the therapeutic time window for blocking IL-18 mediated cardiac inflammation and remodelling, IL-18 nAbs were intraperitoneally injected 1 and 24 h after ISO treatment, respectively. As shown in Figure 6A , administration of IL-18 nAbs at 1 h after ISO-treatment significantly reduced the infiltration area of Mac-3 þ cells (macrophages) in the heart. However, IL-18 nAbs administration at 24 h after ISO-treatment failed to ameliorate macrophage infiltration.
Inflammation is the key mediator for myofibroblast formation and collagen deposition, which lead to cardiac fibrosis. 7 At the 7th day after ISO administration, cardiac interstitial fibrosis was markedly increased, and IL-18 nAbs given at 1 h but not at 24 h after ISO treatment significantly reduced the cardiac fibrosis area ( Figure 6B ). Cardiac fibrosis is well known to increase ventricular stiffness, leading to diastolic dysfunction. Echocardiography demonstrated that at the 7th day after ISO administration, the E/E 0 , reflecting the diastolic function of left ventricle acquired by pulse wave Doppler and tissue Doppler imaging, was significantly increased as compared with vehicletreated controls ( Figure 6C) . Importantly, IL-18 nAbs treatment at 1 h, but not at 24 h, markedly decreased the level of E/E 0 ( Figure 6C ). Taken together, inhibition of IL-18 activity by IL-18 nAbs during the early phase of ISO-induced acute b-AR insult can block not only cardiac inflammation, but also fibrosis and diastolic dysfunction.
Discussion
Our studies provide the first characterization of dynamic changes of inflammatory cytokine proteins caused by acute b-AR insult. We demonstrated that selective activation of IL-18 by inflammasome in the myocardium is a crucial trigger for the cytokine cascade and macrophage infiltration in the heart, which in turn leads to adverse cardiac remodelling. Furthermore, we found that ISO induced inflammasome activation is mediated by the b 1 -AR-ROS pathway. Moreover, we determined a critical time window for blocking IL-18-mediated deleterious inflammatory responses and cardiac malfunction after the onset of b-AR over-activation. Together, our findings identify IL-18 as a promising therapeutic target for numerous heart diseases that involve stress-induced inflammation mediated by b-AR insult. A working model is illustrated in Take home figure.
Inflammation is a common drive for pathological cardiac remodelling after heart injuries, which is well-recognized in myocardial infarction (MI) besides b-AR insults. 11 However, molecular and cellular mechanisms underlying the inflammatory responses in different cardiac diseases are distinct. First, different types of inflammatory cells are recruited to heart in various disease models. Unlike the infiltration of neutrophils and inflammatory monocytes in the infarcted myocardium, 11 our studies clearly demonstrated that M1 macrophages are the primary cells infiltrated into the myocardium upon acute b-AR stimulation. Second, initial inflammatory responses arise from distinct cell types in the heart. After MI, endothelial cells and fibroblasts are activated and express chemokines to recruit inflammatory cells into the heart, which in turn propagate the inflammatory cytokine production. 11 Similarly, cardiac fibroblasts are the primary type of cells for inflammasome activation after myocardial ischaemia/reperfusion injury. 12 In contrast, we found that the initial inflammasome activation is restricted within cardiomyocytes after systemic administration of ISO. In addition, direct activation of inflammasomes by b-AR stimulation can be readily achieved in cultured NMCM without 'priming' with lipopolysaccharide as shown in previous studies. 12, 13 These observations provide an explanation why cardiomyocyte is the primary susceptible target for damages caused by sympathetic overstimulation. 14 In cardiomyocytes, pro-IL-18 is constitutively expressed 15 whereas pro-IL-1b is not detected. 12 Therefore, upon acute b-AR stimulation, activation of inflammasomes specifically in cardiomyocytes results in a rapid cleavage and maturation of pro-IL-18, but not pro-IL-1b. This result is consistent with the previous report that induction of the inflammasome in cardiomyocytes did not activate IL1b after acute MI. 13 Besides the enhancement of inflammasome-dependent cleavage, up-regulated transcription of IL18 and IL-1b can also lead to sustained inflammatory responses. Indeed, increased expression of mRNAs encoding IL-18 and IL-1b has been demonstrated in myocardium in response to sustained chronic b-AR stimulation. 5, 6 Nonetheless, acute b-AR stimulation by a single dose of ISO exposure does not induce transcription of IL-1b or IL-18 (see Supplementary material online, Figure S8 ). Thus, pulsed b-AR insult only causes inflammasome-dependent cleavage and a rapid activation of pro-IL-18. These findings offer a feasible strategy for blocking inflammatory responses soon after acute b-AR insult by targeting the rapid activation of IL-18 that specifically occurred in cardiomyocytes. Indeed we showed that systemic administration of IL-18 nAbs 1 h after ISO-treatment significantly attenuates chemokine production, macrophage infiltration and deleterious cardiac remodelling (Figures 5  and 6 ). In contrast, targeting the later IL-18 activation 24 h after ISO treatment failed to reverse the inflammatory responses.
Cardiomyocytes harbour both the b 1 and b 2 subtypes of b-AR whereas cardiac fibroblasts only express b 2 -AR. 16 The fact that b 1 -AR mediates ISO-induced inflammasome activation further supports our conclusion that inflammasome was initially activated in cardiomyocyte but not cardiac fibroblasts upon ISO treatment (see Supplementary material online, Figure S11 ). b 1 -ARs couple only to Gs proteins whereas b 2 -AR couple to both Gs and Gi proteins. 17 ISO-induced inflammasome activation is mediated mainly by b 1 -ARs not b 2 -ARs probably because that b 2 -AR-Gs-mediated response is negated by the b 2 -AR-Gi-signalling. 17 Inflammasome was rapidly activated in cardiomyocytes after 5 min of ISO treatment, as a result of activation of the b 1 -AR-ROS pathway. Notably, b-AR stimulation can rapidly increase ROS production after 4-6 min of ISO application in rabbit ventricular myocytes. 18 In addition, ROS production is crucial for NLRP3 inflammasome activation. 19 Notably, we found that ISO increases NLRP3 but not NLRC4 level in cardiomyocytes (see Supplementary material online, Figure S14 ) which is consistent with the recent study that NADPH oxidase 4, a source of cellular superoxide anions, is involved in NLRP3 but not NLRC4 inflammasome activation. 20 Similarly to these previous studies, in our model, the rapidly increased ROS production upon ISO treatment is responsible for inflammasome activation in cardiomyocytes. Consistent with our findings that IL-18 mediates acute stressinduced cardiac injuries in mice and sympathetic overactivation increased IL-18 levels in patients, high serum levels of IL-18 were associated with an increased risk of developing cardiovascular disease in the general population. 21 To prevent cardiotoxic effects by sympathetic overactivity, b blockers are recommended for various heart diseases including acute coronary syndromes and stress cardiomyopathy. 3, 22 However, besides pathological inflammatory responses and cardiac remodelling, b-AR activation also induces positive chronotropic, dromotropic, and inotropic effects which are important for normal cardiac function. Because b blockers antagonize both pathological and physiological effects, patients suffer from acute heart failure, heart block and active asthma cannot benefit from b blockers. Novel therapeutics that blocks pathological effects but retain physiological effects by b-AR activation is needed for clinical events when b blockers are contraindicated. Notably, inflammatory responses induced by b-AR activate both protective and injurious pathways. Hence, an optimal therapeutic strategy requires effective suppression of inflammatory cascades while activating reparative pathways. Unlike b blockers, inhibition of IL-18 activity leads to selective suppression of the deleterious inflammatory pathways while retaining protective inflammatory pathways induced by b-AR activation without negative inotropic effects ( Figures 5 and 6 , Supplementary material online, Table S4 ). IL-18 is originally termed as the IFN-c inducing factor and IFNc induction is a major function of IL-18. 15 IFNc level was significantly decreased in the IL-18nAbs group suggesting the effectiveness of IL-18 nAbs in the present study. It is worth mentioning that human IL-18 nAbs, GSK1070806, has been investigated in clinical trials, 23 which was generally safe and well tolerated. Taken together, IL-18 is a promising therapeutic target against numerous cardiac diseases involved b-adrenergic toxicity, especially benefits patients contraindicated for the current clinical usage of b blockers.
Study limitation
We only used 3-4 samples/group, the relatively low numbers of samples, to perform the cytokine array. However, the screening provided an important clue that chemokines form the first wave of cytokines up-regulated in cardiomyocytes, which in turn recruits circulating macrophages to the heart. Further ELISA assays also validated this finding. Importantly, the identified cytokines lead to the further discovery of IL-18 as a novel upstream trigger for cardiac inflammatory cascades upon b-AR insult. In summary, we demonstrated that inflammasome-dependent activation of IL-18 in myocardium is a crucial trigger for the rapid induction of inflammatory cytokines, macrophage infiltrations and subsequent pathological cardiac remodelling elicited by acute b-AR stimulation. Targeting IL-18 at the early stage of acute stress is a promising therapeutic strategy against heart diseases caused by acute stress, such as acute coronary syndrome and stress cardiomyopathy.
